Copper aspirinate Copper aspirinate Copper(II) aspirinate is an aspirin chelate of copper(II) cations (Cu). It is used to treat rheumatoid arthritis. Copper aspirinate can be prepared by several methods. In one route of preparation, an excess of acetylsalicylic acid is dissolved in aqueous sodium carbonate. Sodium hydroxide is not suitable for this purpose, because it will hydrolyse acetylsalicylic acid ("ASA") into salicylic acid and sodium acetate. The resulting solution is then filtered to remove any undissolved acetylsalicylic acid and is mixed with a solution containing Cu cations (copper(II) sulfate is suitable), precipitating bright blue crystals of copper aspirinate immediately. The crystals can
Nonsteroidal anti-inflammatory drug inflammation and also used willow bark to mitigate them. On 25 April 1763, Edward Stone wrote to the Royal Society describing his observations on the use of willow bark-based medicines in febrile patients. The active ingredient of willow bark, a glycoside called salicin, was first isolated by Johann Andreas Buchner in 1827. By 1829, French chemist Henri Leroux had improved the extraction process to obtain about 30g of purified salicin from 1.5 kg of bark. By hydrolysis, salicin releases glucose and salicylic alcohol which can be converted into salicylic acid, both in vivo and through chemical methods. The acid is